



Innovative Science for a Healthier Planet

Workshop on Second Generation Bioethanol and Biorefining 2017

João Paulo Cherubim

Manufacturing and PD Director

November 31, 2017



Forward-Looking Statements

This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected returns from funded development, anticipated revenue, including revenue from product sales, collaborations and value share payments, expected gross profit and margin, the anticipated development and commercialization of Amyris's product pipeline and revenue relating thereto, expected production costs and time to market, anticipated production capacity expansion, including the timing thereof, the anticipated growth rates of Amyris's target markets and Amyris's expected market share and revenue by target market, expected annual product sales, revenue and growth rate, anticipated corporate events, including a reverse stock split, expected financing and debt reduction in 2017 and the impact of such financing and debt reduction, expected revenue growth in 2017 and beyond, anticipated improvements of Amyris's balance sheet and product margins, and expectations regarding Amyris's financial and operational results and ability to achieve its business plan in 2017 and beyond, that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, timing and execution risks associated with manufacturing, uncertainty regarding consummating potential transactions, including the timing thereof, and growth in sales, potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on November 9, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as result of new information, future events, or otherwise.




A decade of progress

- Amyris was founded in 2003 by scientists from the University of California, Berkeley.
- In 2005, with a grant from the Bill & Melinda Gates Foundation, developed technology for the production of effective anti-malarial drug precursor, artemisinin, now in market.
- Following various rounds of venture funding and strategic investments by TOTAL and Temasek, Amyris listed shares on NASDAQ in September 2010.
- In 2011, first production and sales of products from Biofene[®], Amyris's renewable farnesene.
- In 2013, completed first year of production at our purpose-built biorefinery in Brotas, Brazil.
- This year we are executing on business plan including scale up of technology to produce a high-value fragrance oils, vitamins, sweeteners in addition to farnesene for multiple applications.




Our innovative science, world class robotics, and deep data analytics drive rapid product development




Cellular programming

Modify cellular DNA to add new functionality to cells



Analytics

Collect high throughput, rich data to understand how DNA changes impact cell functionality






Data Science

Represent the cell computationally & use machine learning to drive faster and larger improvements

Amyris scientists build and test 100,000 strains per month

Amyris pioneered integrated robotic work cells




Industry-Leading Proprietary Tools Make Amyris the Leading Industrial Bio-Engineering & Production Company

Capacity:

- 18,000 low-cost DNA assemblies/year at 95% accuracy
- Targeted DNA integration at up to 6 loci per transformation
- Fastest, most efficient software allows scientists to “code” DNA directly into cells
- Integrated data management enables machine learning
- Ability to test over 1M unique strains per year

Average time from concept to target production cost is now less than 12 months



We are winning today in high-growth markets

Health & Wellness



Aging population

Healthcare concerns

Food consumption

Health & Nutrition

Global Shifts



Growing population

Increased wealth

Urbanization

Personal Care

Market Volatility



Sustainability push

Resource allocation

Supply chain security

**Performance
Materials**



Leading partners remove product & market risk

Sample Partners

2021 Targets

Health & Nutrition

- Pharma
- Nutraceuticals
- Food Ingredients



60-70% Gross Margin

Personal Care

- Fragrance ingredients
- Skincare
- Cosmetic Actives



50-60% Gross Margin

Performance Materials

- Lubricants
- Polymers
- Adhesives



30-40% Gross Margin

\$60M Collaboration
Revenue



Our distinctive and advantaged business model removes product and market risk while funding development

Benefits of model

- Covers direct R&D costs
- High investment returns from funded development
- Long-term annuity from product profit share

1 Target



Upfront
funding

2 Develop



Milestone
payments from
partner

3 Supply



Sale and profit on
shipment to
partner

4 Profit split



Split profit on
partners
downstream sale



Our Current Collaboration Portfolio

Active/revenue producing collaborations

14

Contracted products

>100

Est. annual product sales at maturity

>\$2B


- 
1. Flavor and fragrance
 2. Flavor and fragrance
 3. Farnesene
 4. Food ingredient
 5. Multiple molecules (DARPA, 400+ for development)
 6. Isoprene
 7. Ethanol
 8. Cosmetic ingredients
 9. Small molecule Oncology
 10. Antibody organism development
 11. Technology access partnership (40+ molecules)
 12. Small molecule Antibiotic
 13. Farnesene (cellulosic)
 14. Food ingredients/nutraceuticals*

** Only MOU signed; expect to be closed in Q4*



Products commercialized, or in pipeline, drive targets

Product & collaborations revenue, ex. Fuels, \$M



Sugar reduction market is a step-out opportunity


None of these taste good!

"Artificial"

- Saccharin (Sweet 'N Low)
- Aspartame (Equal, NutraSweet)
- Sucralose (Splenda)



"Natural"

- Stevia (Truvia)
- Sugar alcohols (polyols) such as mannitol, sorbitol, xylitol
- Monk fruit extract



In 2017 sugar-replacement market is \$8.7B
9% of \$97B sweeteners

Amyris technology will disrupt today's stevia-based sugar replacements




We plan to launch our first products in 1st-Half 2018




Vitamins help grow healthy, heavier animals very fast – providing protein the world needs and keeping farmers happy


Antimicrobial use has declined in Europe (mt per year)



Vitamin E market growth (global, \$bn)



Amyris vitamin revenue targets 2016-2021, \$M



- Europe has led the way in regulatory reduction of antimicrobial growth promoters
- U.S. FDA has updated guidance to discourage antimicrobial overuse (2017)
- China launched a national program to reduce overuse by 2020 (2016)
- A WHO study of Danish industry concluded no serious economic consequence of the phase-out (2002)

Competitive advantage

Lowest cost	Highest purity	Protected technology
Vitamin E 40% lower than legacy technology	Directly produces Vitamin E oil (95% purity)	Farnesene-based chemistry

Antibiotics: EU data (bi.ema.europa.eu), 2016, 8 countries with data for this range

Vitamin E: Transparency Market Research & Global Market Insights Inc., 2016



We have proven commercial production capability




Amyris Biorefinery

- Brotas 1 with up to 24,000 mt of Farnesene capacity
- We've produced and sold >23,000,000 kg of products from our plant
- Four different molecules, both liquids and solids




Brotas II plant



- Brotas 2, a specialty product facility is under construction, targeted on-line 1Q 2019



Leading Shareholders and Board of Directors



John Doerr
KPCB
KLEINER
PERKINS
CAUFIELD
BYERS



Christophe Vuillez
TOTAL



HH Sheikh Abdullah
bin Khalifa Al Thani
BIOLDING
INVESTMENTS



Geoff Duyk
TPG
BIOTECH



Bram Klaijssen
Former President,
Cargill Asia
Cargill



Margo Georgiadis
Chief Executive Officer
Mattel
MATTEL



Fernando Reinach
Managing Partner,
Pitanga Fund



Neil Williams
CFO, Intuit
intuit.



Patrick Yang
Former Global Head,
Technical Operations
Roche/Genentech
Roche



Carole Piwnica
Director, NAXOS



John Melo
AMYRIS



One day soon all
products will be
made our way





Thanks!!